<DOC>
	<DOCNO>NCT02874859</DOCNO>
	<brief_summary>This non-interventional retrospective study efficiency tolerance intravitreal injection Aflibercept vitrectomized eye diabetic macular oedema</brief_summary>
	<brief_title>Intravitreal Aflibercept InjectiOn Vitrectomized Eyes Treatment Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetic macular edema ( DME ) lead cause blindness among people work age . Treatment DME include blood pressure glycemic control , grid laser , intravitreal injection steroid ( acetonide triamcinolone , dexamethasone implant , fluocinolone implant ) anti-Vascular endothelial growth factor ( VEGF ) therapy ( Bevacizumab , Ranibizumab , Aflibercept ) ( 2015 ) . The advent anti-VEGF therapy revolutionize management DME . Aflibercept , one drug group recently approve France . However , report efficacy tolerance Aflibercept vitrectomized eye diabetic macular oedema . In study , order prove efficiency tolerance Aflibercept , data collect anonymous way medical record patient receive treatment Aflibercept past .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Diabetic patient age 19 90 year old Patients follow characteristic begin Aflibercept therapy : HbA1c &lt; 9 % Diabetic macular oedema central affect Visual acuity 1/20 5/40 ( 20 70 letter ETRS ) Patients vitrectomy 3 month ago Patients receive antiVEGF treatment treatment diabetic macular edema 3 month begin injection Patients refuse collection data medical record Patients macular ischemia 1500Âµm diagnosed via avascular central fluorescein angiography inclusion Patients recent cardiovascular incident ( heart attack , stroke date less 3 month inclusion ) Pregnancy moment inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DIABETIC RETINOPATHY</keyword>
	<keyword>Intravitreal aflibercept</keyword>
</DOC>